Model systems in drug discovery: chemical genetics meets genomics.
Animal model systems are an intricate part of the discovery and development of new medicines. The sequencing of not only the human genome but also those of the various pathogenic bacteria, the nematode Caenorhabditis elegans, the fruitfly Drosophila, and the mouse has enabled the discovery of new drug targets to push forward at an unprecedented pace. The knowledge and tools in these "model" systems are allowing researchers to carry out experiments more efficiently and are uncovering previously hidden biological connections. While the history of bacteria, yeast, and mice in drug discovery are long, their roles are ever evolving. In contrast, the history of Drosophila and C. elegans at pharmaceutical companies is short. We will briefly review the historic role of each model organism in drug discovery and then update the readers as to the abilities and liabilities of each model within the context of drug development.
Carroll
Pamela M
PM
Department of Applied Genomics, Bristol-Myers Squibb, Pennington NJ 08534, USA.
Dougherty
Brian
B
Ross-Macdonald
Petra
P
Browman
Kailtin
K
FitzGerald
Kevin
K
D000818:Animals; D004345:Drug Industry / Q000295:instrumentation* / Q000379:methods*; D005827:Genetics, Microbial / Q000379:methods / Q000639:trends*; D023281:Genomics / Q000379:methods* / Q000639:trends*; D051379:Mice; D008817:Mice, Mutant Strains; D023421:Models, Animal